Medications

AAD: Long-term improvement seen with ruxolitinib in vitiligo

For patients with nonsegmental vitiligo, continued improvement in seen during a long-term extension of ruxolitinib treatment, according to study presented at the annual meeting of the American Academy of Dermatology, held ...

Medications

Not enough new antibiotics in the pipeline, WHO review concludes

A review from WHO on the number of new antibiotics currently in the pipeline shows that just 12 new antibiotics have entered the market in the five years from 2017-21. And there are far too few (just 27) under development ...

Vaccination

Leaders say 'never again' to vaccine inequity

Three years since the Covid pandemic began, nearly 200 prominent world figures called on Saturday for the vaccine inequity seen during the crisis to be relegated to history.

Medications

Benefits of valoctocogene roxaparvovec persist in hemophilia A

For patients with hemophilia A, factor VIII activity and bleeding reduction persist at two years after gene transfer with valoctocogene roxaparvovec, which delivers a B-domain-deleted factor VIII coding sequence with an adeno-associated ...

Genetics

Gene therapy beneficial for patients with hemophilia B

For patients with hemophilia B, one infusion of adeno-associated virus 5 (AAV5) vector expressing the Padua factor IX variant (etranacogene dezaparvovec) is noninferior and superior to prophylaxis with factor IX, according ...

page 11 from 40